scholarly journals The Evolving Treatment Options for Diabetic Macular Edema

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Atul Jain ◽  
Neeta Varshney ◽  
Colin Smith
Keyword(s):  
Diabetic Retinopathy ◽  
Visual Impairment ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Treatment Options ◽  
Previous Treatment ◽  
Common Cause ◽  
Working Age

Diabetic retinopathy (DR) is the leading cause of vision loss in working-age adults, and diabetic macular edema (DME) is the most common cause of visual impairment in individuals with DR. This review focuses on the pathophysiology, previous treatment paradigms, and emerging treatment options in the management of DME.

Aflibercept for the Treatment of Diabetic Retinopathy and Diabetic Macular Edema

2018 ◽  
pp. 147-154
Keyword(s):  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Developed Countries ◽  
Inhibitory Effect ◽  
Duration Of Action ◽  
Anti Vegf ◽  
Working Age

Diabetic macular edema (DME) is a common complication of diabetic retinopathy (DR) and is a leading cause of vision loss in developed countries during the working age. Understanding the role of vascular endothelial growth factor (VEGF) in the pathogenesis of DME has emphasized the importance of using anti-VEGF agents in treatment. Anti-VEGF drugs such as pegaptanib, ranibizumab, bevacizumab, and aflibercept have been studied in the treatment of DME. Aflibercept is a recombinant fusion protein with an inhibitory effect on VEGF-A, VEGF-B, placental growth factor (PIGF) 1 and 2. It is believed that this agent has a longer duration of action than other anti-VEGF molecules due to its high-affinity binding to the VEGF molecule. This review summarizes the pharmacological properties of aflibercept in terms of clinical efficacy, use, and tolerability in the treatment of DME.

scholarly journals Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema

2020 ◽  
Vol 12 ◽  
pp. 251584142095051 ◽  
Author(s):  
Ashish Markan ◽  
Aniruddha Agarwal ◽  
Atul Arora ◽  
Krinjeela Bazgain ◽  
Vipin Rana ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Imaging Modality ◽  
Microvascular Complications ◽  
Response To Treatment ◽  
Fundus Photography ◽  
Imaging Biomarkers ◽  
Potential Contribution

Diabetic retinopathy is one of the major microvascular complications of diabetes mellitus. The most common causes of vision loss in diabetic retinopathy are diabetic macular edema and proliferative diabetic retinopathy. Recent developments in ocular imaging have played a significant role in early diagnosis and management of these complications. Color fundus photography is an imaging modality, which is helpful for screening patients with diabetic eye disease and monitoring its progression as well as response to treatment. Fundus fluorescein angiography (FFA) is a dye-based invasive test to detect subtle neovascularization, look for areas of capillary non-perfusion, diagnose macular ischemia, and differentiate between focal and diffuse capillary bed leak in cases of macular edema. Recent advances in retinal imaging like the introduction of spectral-domain and swept source-based optical coherence tomography (OCT), fundus autofluorescence (FAF), OCT angiography, and ultrawide field imaging and FFA have helped clinicians in the detection of certain biomarkers that can identify disease at an early stage and predict response to treatment in diabetic macular edema. This article will summarize the role of different imaging biomarkers in characterizing diabetic retinopathy and their potential contribution in its management.

scholarly journals Update on the Management of Diabetic Macular Edema

2017 ◽  
Vol 10 (01) ◽  
pp. 52
Author(s):  
Shawn M Iverson ◽  
W Lloyd Clark ◽  
◽  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Treatment Options ◽  
Current Treatment ◽  
Treatment Modalities ◽  
Vascular Endothelial ◽  
Clinical Practices ◽  
Working Age ◽  
Endothelial Growth Factor ◽  
Review Current

Diabetic macular edema (DME) is a treatable sequela of diabetic retinopathy and a significant cause of visual morbidity among working age individuals worldwide. While anti-vascular endothelial growth factor (anti-VEGF) agents are first-line agents in the management of DME, corticosteroids and laser therapy can play a role as well. Despite a growing understanding of best clinical practices, many patients respond unpredictably to therapy. This article will briefly review current treatment modalities and discuss future treatment options for managing DME.

scholarly journals Postmarketing safety surveillance of dexamethasone intravitreal implant in the treatment of visual impairment due to diabetic macular edema in India

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Unnikrishnan Nair ◽  
◽  
Vishali Gupta ◽  
Mohita Sharma ◽  
Shrinivas Joshi ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Adverse Events ◽  
Visual Impairment ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Surveillance Study ◽  
World Health ◽  
Diabetic Patients

Abstract Background Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. As India has the second largest population of diabetic patients worldwide, availability of various treatment options for DME is essential. This postmarketing surveillance study was conducted to fulfill a commitment to the Regulatory Authority of India to examine the safety of dexamethasone intravitreal (DEX) implant over 1 year in Indian patients with DME receiving ≥1 DEX implant for DME-related visual impairment in clinical practice. Methods This observational, prospective, non-interventional study enrolled patients aged ≥18 years scheduled to receive DEX implant for DME-related visual impairment. Baseline demographics, medical history, date of last DEX implant injection, detailed information about adverse events (AEs), AEs of special interest (AESIs), serious AEs (SAEs), and adverse drug reactions (ADRs) reported during postinjection visits and investigator telephone calls were collected. Primary outcome measures were treatment-emergent AE (TEAE), AESI, SAE, and ADR occurrences. Results Of the enrolled patients (19 sites throughout India; n = 250), 84 had received DEX implant previously; mean (standard deviation; SD) duration between prior and study entry dose was 199.4 (156.0) days, and 91 (36.4%) had ≥1 prior ophthalmic condition. Over a mean of 182.6 (88.6) follow-up days (min–max: 0–364 days), 22 TEAEs were reported by 7 (2.8%) patients, 6 of whom had previously received DEX. AESIs of increased IOP (n = 3, 6 events) and glaucoma (n = 1, 1 event) were considered non-serious, of mild/moderate severity, and related to DEX treatment. Eyelid ptosis was reported in 1 patient (1 event). Nonocular AEs included cardiac AEs (n = 3, 4 events), pyrexia (n = 1, 2 events), and dyspnea (n = 1, 2 events). Three (1.2%) patients had 12 serious AEs; most were cardiac disorders; all were unrelated to DEX treatment. Two (0.8%) deaths were considered unrelated to treatment. Conclusions Based on voluntary reporting of adverse events in this surveillance study, DEX implant for treatment of DME-related visual impairment in the Indian population demonstrated a favorable safety profile with few treatment-related TEAEs (none were considered serious) during the 1-year follow-up. These data supplement previous findings and confirm the safety of DEX implant in this population during usual clinical practice. Trial registration World Health Organization Clinical Trials Registry: CTRI/2017/04/008396. Registered 24 April 2017.

Subthreshold Laser and Subliminal (Micropulse) Laser in Diabetic Retinopathy and Diabetic Macular Edema

2018 ◽  
pp. 177-184
Keyword(s):  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Collateral Damage ◽  
Micropulse Laser ◽  
Working Age ◽  
Visual Acuity Loss ◽  
Subthreshold Laser ◽  
Conventional Laser

Diabetic macular edema (DME) is one of the main causes of a significant reduction in visual acuity in working-age adults and is the most common cause of visual acuity loss from diabetic retinopathy. Most of the studies have shown that the ability of the conventional laser to maintain or improve visual acuity is limited, possibly because of the development of retinal scars, which decrease the potential for improved visual acuity. Subthreshold laser and subliminal (micropulse) laser has the potential to reduce DME with better visual acuity results compared with conventional laser, as it does not cause collateral damage in the retina. These lasers cannot cause permanent damage to the retina. This article mentions subthreshold laser, and subliminal (micropulse) laser in diabetic retinopathy and diabetic macular edema.

scholarly journals A Transfer Learning Approach for Diabetic Retinopathy and Diabetic Macular Edema Severity Grading

2021 ◽  
Vol 35 (6) ◽  
pp. 497-502
Author(s):  
Nida Nasir ◽  
Neda Afreen ◽  
Ranjeeta Patel ◽  
Simran Kaur ◽  
Mustafa Sameer
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Transfer Learning ◽  
Learning Approach ◽  
Learning Technique ◽  
Working Age ◽  
Severity Grading ◽  
Aided Diagnosis

Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) are complication that occurs in diabetic patient especially among working age group that leads to vision impairment problem and sometimes even permanent blindness. Early detection is very much needed for diagnosis and to reduce blindness or deterioration. The diagnosis phase of DR consumes more time, effort and cost when manually performed by ophthalmologists and more chances of misdiagnosis still there. Research community is working on to design computer aided diagnosis system for prior detection and for DR grading based on its severity. Ongoing researches in Artificial Intelligence (AI) have set out the advancement of deep learning technique which comes as a best technique to perform analysis and classification of medical images. In this paper, research is applied on Resnet50 model for classification of DR and DME based on its severity grading on public benchmark dataset. Transfer learning approach accomplishes the best outcome on Indian Diabetic Retinopathy Image Dataset (IDRiD).

Anti-VEGF Deficiency, Treatment Resistance, Pharmaceutical Changes and Combined Treatments in Diabetic Macular Edema

2018 ◽  
pp. 165-169
Keyword(s):  
Diabetic Retinopathy ◽  
Combination Therapy ◽  
Visual Impairment ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Treatment Resistance ◽  
Developed Countries ◽  
Combined Treatments ◽  
Anti Vegf ◽  
Treatment Switch

Diabetic retinopathy is the most important cause of blindness in developed countries today. The most important cause of visual impairment is complications related to diabetic macular edema (DME) and proliferative retinopathy. Intravitreal anti-VEGF agents are the first treatment option for central involvement in diabetic macular edema (DME). Despite anti-VEGF agents, some cases are refractory (persistent) to multiple anti-VEGF treatments. In this review, unresponsiveness to anti-VEGF treatment, switch, and combination therapy in DME is mentioned.

Clinical Diagnosis and New Classification of Diabetic Retinopathy and Diabetic Macular Edema

2018 ◽  
pp. 119-123
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Diabetic Patients ◽  
Common Causes ◽  
Diagnosis Classification

Diabetic retinopathy and diabetic macular edema are the most common causes of preventable blindness among the working class in many countries. The prevalence of diabetic macular edema, which is frequently associated with vision loss, is increasing. Classification of diabetic retinopathy is essential for precise and punctual treatment and follow-up, and ultimately for enhancing the quality of life of diabetic patients. Studies in recent years have shared protocols for diagnosis, classification, and follow-up.

Sign in / Sign up

Export Citation Format

Share Document